Loading
A phase 3 trial of Abemaciclib and Prednisone in prostate cancer, run by Eli Lilly and Company, active and no longer recruiting.
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) is a phase 3 interventional study registered as NCT05288166 by Eli Lilly and Company, with 925 participants enrolled, started 2022-04-14 and due to reach its primary completion in 2024-02-15. Interventions recorded: Abemaciclib, Abiraterone, Prednisone or Prednisolone and Placebo for Abemaciclib. Results have been posted on the registry.
Shares Abemaciclib, Eli Lilly (incl. Loxo), CDK4/6 inhibitors and the tag pipeline.
Shares Abemaciclib, Eli Lilly (incl. Loxo), CDK4/6 inhibitors and the tag pipeline.
Shares Abemaciclib, Eli Lilly (incl. Loxo), CDK4/6 inhibitors and the tag pipeline.
Shares Abemaciclib, CDK4/6 inhibitors and the tag pipeline.
Shares Abemaciclib, Eli Lilly (incl. Loxo), CDK4/6 inhibitors and the tag pipeline.
Shares Abemaciclib, CDK4/6 inhibitors and the tag pipeline.
Shares Abemaciclib, Eli Lilly (incl. Loxo), CDK4/6 inhibitors and the tag pipeline.
Shares Abemaciclib, CDK4/6 inhibitors and the tag pipeline.